The U.S. HSV1 treatment market is projected to register a healthy CAGR of 11.9% in the forecast period of 2020 to 2027. The new market report contains data for the historic year 2018, the base year of calculation is 2019 and the forecast period is 2020 to 2027

Market Segmentation:
U.S. HSV1 Treatment Market, By Type (Cold Sores, Genital Herpes), Occurrence (Primary Herpes, Recurrent Herpes), Treatment (Drugs, Vaccines), Route of Administration (Oral, Topical, Parenteral), Population Type (Neonates, Paediatrics and Adults), Gender (Male and Female), End User (Hospitals, Specialty Clinics, Home Healthcare and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy & Others) Industry Trends and Forecast to 2027

Some of the major factors contributing to the growth of the U.S. HSV1 treatment market are:

- Increasing in prevalence of HSV infection
- Increase modes of transmission of the infectious disease

Market Players:

The key market players for the U.S. HSV1 treatment market are listed below:

- GlaxoSmithKline plc
- Apotex Inc.
- Mylan N.V.
- Cipla Inc.
- Teva Pharmaceuticals USA, Inc. (A Subsidiary of Teva Pharmaceutical Industries Ltd.)
- Avet Pharmaceuticals Inc.
- Amneal Pharmaceuticals LLC
- Tolmar Pharmaceuticals, Inc
- Perrigo Company plc
- Ortho Dermatologics’ (A Part of Bausch Healthcare Companies Inc.)
- F. Hoffmann-La Roche Ltd
- Macleods Pharmaceuticals Ltd
- Fresenius Kabi USA (A Subsidiary of Fresenius Kabi AG)
- Dr. Reddy’s Laboratories Ltd.
- EXCELL BIOTECH
- NANOVIRICIDES, INC.
- Glenmark Pharmaceutical Inc., USA (A Subsidiary of Glenmark Pharmaceuticals Ltd.)
- X-Vax Technology, Inc.
- AiCuris GmbH & Co. KG
- Mustang Bio (A Subsidiary of Fortress Biotech, Inc.)
- Sorrento Therapeutics, Inc.